A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 340 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR A New FDA Approval Furthers the Role of Genomics in Cancer... July 8, 2020 Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in... March 3, 2021 Girl’s New College Dorm Has Perfect View Of The Hospital Room... September 30, 2021 Cancer Moonshot℠ Workshop Highlights Recent Research Advances March 4, 2020 Load more HOT NEWS Newly Discovered ‘Don’t Eat Me’ Signal May be a Target for... Worried Cancer Patients Face Delayed Treatment Because Of Pandemic Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients... COVID-19 May Have Saved a Woman’s Life by Helping Her Discover...
